" class="no-js "lang="en-US"> ADC Therapeutics Archives - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells

Sort by:

Date

Top Post

NHS Slashes Longest Elective and Cancer Waits for Patients | MTA

NHS Slashes Longest Elective and Cancer Patient Waiting Lists

The number of people waiting over 18 months for NHS care has fallen again despite […]

Read more

Drug Development

 IntoCell Enters into Development and License Option Agreement with ADC Therapeutics | PTF

IntoCell Enters into Development and License Option Agreement with ADC Therapeutics

IntoCell has announced the signing of a Material Transfer Agreement (MTA) with option to license […]

Diseases

 ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® for the Treatment of Lymphoma | PTF

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® for the Treatment of Lymphoma

ADC Therapeutics SA and Swedish Orphan Biovitrum AB (Sobi) has announced the European Commission (EC) […]

  1. Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

    Clinical Trials

     Read more
  2. Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors

    Appointments

     Read more
  3. Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics

    News

     Read more
  4. Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer

    News

     Read more
  5. Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

    Diseases

     Read more